NCT00613665已完成1 期
Phase I, Randomized, Controlled, Single-blind, Dose-Ranging and Schedule-Finding Study of the Safety, Tolerability, and Immunogenicity of Chiron Helicobacter Pylori Vaccine in Healthy, Helicobacter Pylori-negative Adults
Novartis Vaccines2 个研究点 分布在 1 个国家目标入组 113 人开始时间: 2001年2月最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 113
- 试验地点
- 2
- 主要终点
- Safety measures: injection site and systemic reactions
研究概览
简要总结
This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ages 18-40
- •Negative for H. pylori infection
- •Contraception for females
排除标准
- •Present or past H. pylori infection
- •Medically significant gastroduodenal disease
- •Recent corticosteroid use
- •Bleed diathesis
- •Use of antibiotics used to treat H. pylori infection
结局指标
主要结局
Safety measures: injection site and systemic reactions
时间窗: 5 months
次要结局
- Immunogencity measures: antigen-specific antibodies and cellular immune response(5 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid TumorsEsophagus CancerPancreas CancerColorectal CancerGastric CancerNon-small Cell Lung CancerBile Duct CancerBreast CancerNCT06043466Chongqing Precision Biotech Co., Ltd30
Unknown
不适用
the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of KneeDefect of Articular CartilageArticular Cartilage Disorder of KneeArticular Cartilage, Knee DegenerationNCT02524509Sewon Cellontech Co., Ltd.50
已完成
1 期
A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy AdultsRift Valley FeverRVFNCT04672824University of Oxford30
已完成
1 期
Study of Novel Types 1 and 3 Oral Poliomyelitis VaccinesPoliomyelitisNCT04529538PATH205
已完成
1 期
A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative AdultsHIV SeronegativityHIV InfectionsNCT00002204Chiron Corporation40